Baumgartner, Annette http://orcid.org/0000-0002-1033-6945
Rauer, Sebastian
Hottenrott, Tilman
Leypoldt, Frank
Ufer, Friederike
Hegen, Harald
PrĂ¼ss, Harald
Lewerenz, Jan
Deisenhammer, Florian
Stich, Oliver
Article History
Received: 24 August 2018
Revised: 23 October 2018
Accepted: 25 October 2018
First Online: 12 November 2018
Compliance with ethical standards
:
: S.R. received consulting and lecture fees, grant and research support from Bayer Vital GmbH, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis and Teva. He is a founding member of ravo Diagnostika GmbH, Freiburg. F.L. disclosures receiving speakers honoraria from Grifols, Teva, Biogen, Merck, Roche and Fresenius. He is employed by an academic institution offering commercial antibody testing. H.H. has participated in meetings sponsored by received speaker honoraria or travel funding from Bayer, Biogen, Merck, Novartis, Sanofi-Genzyme, Teva, and received honoraria for acting as consultant for Teva. J.L. has received honoraria for speaking and travel grants from Bayer, TEVA, CHDI and the Movement Disorders Society. F.D. has participated in meetings sponsored by or received honoraria for acting as an advisor/speaker for Biogen Idec, Celgene, Genzyme-Sanofi, Merck, Novartis Pharma, Roche, and TEVA ratiopharm. His institution has received research grants from Biogen and Genzyme Sanofi. He is section editor of the MSARD Journal (Multiple Sclerosis and Related Disorders). A.B., T.H., F.U., H.P. and O.S. report no conflicts of interest with this study. None of the authors has any financial or personal relationships with individuals or organisations that could inappropriately influence this submission.
: The authors confirm that the study is in accordance with ethical standards. The local ethics committee approved the study.